Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 42, Issue 2, 1991, Pages 146-150

  Jacob, Joseph H ^a   Gershenson, David M ^a   Morris, Mitchell ^a   Copeland, Larry J ^a   Burke, Thomas W ^a   Wharton, J Taylor ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN;

ADJUVANT CHEMOTHERAPY; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMAN; MIDDLE AGE; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0025947320     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/0090-8258(91)90335-3     Document Type: Article

References (17)

1. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
2. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
3. Surgery for common epithelial tumors of the ovary
4. Stage III epithelial ovarian cancer: The role of maximal surgical reduction
5. Primary cytoreductive surgery for epithelial ovarian cancer
6. Long-term survival after chemotherapy for advanced epithelial ovarian cancer
7. Prognostic implications of large volume residual disease in patients with advanced stage epithelial ovarian cancer
8. Histological typing of ovarian tumors
9. Epithelial carcinoma of the ovary: Prognostic importance of histologic grade
10. Survival for cancer patients following treatment
11. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma
12. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity
13. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III–IV epithelial ovarian carcinoma
14. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma
15. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer
16. Early second surgery in bulky epithelial ovarian cancer (EOC) does not improve survival: Results of a randomized study (Abstract)